Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus
- 8 October 2025
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (12) , 7535-7543
Abstract
Aims: There is current apprehension among some clinicians and conflicting evidence regarding ocular complications in relation to Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). We aimed to generate multi‐disciplinary, expert‐led consensus recommendations relating to ocular complications to facilitate optimum prescribing of GLP‐1RAs. Materials and Methods: A modified Delphi was conducted following the ACcurate COnsensus Reporting Document (ACCORD) for Delphi research. A structured literature review informed an anonymous online Delphi questionnaire, followed by a virtual consensus meeting. Eligible participants included ophthalmologists, diabetologists, and obesity specialists practising in Europe. Results: Responses from 58 participants across 17 countries were analysed. Respondents agreed that diabetic retinopathy (DR) worsening events are primarily linked to rapid blood glucose‐lowering, rather than a direct drug effect. The benefits of GLP‐1RAs were deemed to outweigh potential ocular risks and should not limit access to these medicines. Prescribers should ensure that people with diabetes are screened for diabetic retinopathy before commencing GLP‐1RAs, particularly in high‐risk populations (>10 years duration and/or poor glucose control, (haemoglobin A1c [HbA1c] >10% or 86 mmol/mol)). When prescribing GLP‐1RA to those with sight loss in one eye and/or prior history of non‐arteritic anterior ischaemic optic neuropathy (NAION), the risk of ocular complications should be discussed. The Delphi study highlighted current uncertainty in the evidence, with some topics on the relationship between GLP‐1RAs and ocular complications reaching limited consensus. Conclusions: Further research is needed into the direct effects of GLP‐1RAs on the retina and ocular complications. New evidence should be disseminated rapidly to optimise outcomes and safety.Keywords
This publication has 36 references indexed in Scilit:
- Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical PracticeOphthalmology Retina, 2025
- Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort studyDiabetologia, 2025
- Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysisScientific Reports, 2025
- Semaglutide and Nonarteritic Anterior Ischemic Optic NeuropathyJAMA Ophthalmology, 2025
- Association between Semaglutide and Nonarteritic Anterior Ischemic Optic NeuropathyOphthalmology, 2024
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideJAMA Ophthalmology, 2024
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-AnalysisEndocrine Practice, 2023
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsThe Lancet Diabetes & Endocrinology, 2021
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016
- Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studiesJournal of Clinical Epidemiology, 2014